Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis

Overview of attention for article published in JNCI: Journal of the National Cancer Institute, May 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 8 news outlets
twitter: 89 X users

facebook: 2 Facebook pages
guideline: 2 clinical guideline sources

Readers on

mendeley: 205 Mendeley

So far, Altmetric has seen 102 X posts from 89 X users, with an upper bound of 381,521 followers.

@KrishanJethwa We don't know what % were BR, but what would you expect to see as mOS in what I imagine is a mostly BR population? https://t.co/M3YfavCXFB suggests mOS 22 mo? Is 30mo from Alliance the outlier? Do we expect 1 cycle of FOLFIRINOX to improv…

RT @weoncologists: Just out 📢at @JNCI_Now patient-level metaanalysis👩‍⚕️👨‍⚕️🔬📰of Borderline Resectable #PancreaticCancer 🧬shows patients tr…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 98 additional X posts.